Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The Schepens Eye Research Institute Inc. currently has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 4 distinct examiners, meaning each pending matter is assigned to a different individual. Furthermore, the prosecution is spread across 4 distinct art units, indicating that each of the institute's pending matters is being evaluated in a different technical department within the patent office.
The busiest examiner for this portfolio is DAVIS, BRIAN J, who is responsible for 1 pending office action. Given that there are 4 pending office actions in total, the workload is perfectly distributed among the examiners. This means that the applicant must navigate different examiner perspectives and multiple sets of art unit guidelines simultaneously. The lack of overlap in examiners or art units suggests a diverse range of biological and pharmaceutical innovations being prosecuted.
Practitioners for The Schepens Eye Research Institute Inc. must be prepared for a variety of feedback, as the pending office actions are not concentrated under any single individual or department. Since DAVIS, BRIAN J and the other examiners each manage only a single action, there is no opportunity to leverage a single examiner's preferences across multiple cases. The focus on Biotechnology & Pharmaceuticals provides the only common thread across these distinct art units, requiring a versatile prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.6% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833889 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | HELM, CARALYNNE E | — |
| 18312848 | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | HELM, CARALYNNE E | — |
| 18312848 | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | HOERNER, PAUL ELLSWORTH | — |
| 16609184 | METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS | WANG, CHANG YU | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1615 | 1 |
| 3774 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833889 | NUCLEIC ACID ENCODED TRANSCRIPTION FACTOR INHIBITORS | DAVIS, BRIAN J | 1614 | §112 | Final Rejection | — | Pending | Jul 27, 2024 |
| 18256277 | COMPOSITIONS AND METHODS FOR MUCOSAL DRUG DELIVERY | HELM, CARALYNNE E | 1615 | §103§112 | Final Rejection | — | Pending | Jun 07, 2023 |
| 18312848 | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | HOERNER, PAUL ELLSWORTH | 3774 | §102§103§112 | Non-Final OA | — | Pending | May 05, 2023 |
| 16609184 | METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS | WANG, CHANG YU | 1675 | §102 | Non-Final OA | — | Pending | Oct 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial